| Mar 26 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 99.33M | $ 108.33M | $ 108.10M | $ 76.70M | $ 79.66M |
| Gross Profit | $ 54.41M | $ 56.58M | $ 60.04M | $ 37.93M | $ 42.01M |
| Operating Income | $ 5.83M | $ 8.22M | $ 7.61M | $ -12.38M | $ -1.38M |
| EBITDA | $ 12.66M | $ 16.81M | $ 14.65M | $ 14.55M | $ -23.61M |
| Net Income | $ -2.39M | $ 2.25M | $ 1.22M | $ -2.88M | $ -28.26M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 6.52M | $ 23.97M | $ 13.07M | $ 10.02M | $ 18.70M |
| Total Assets | $ 147.28M | $ 171.84M | $ 161.33M | $ 139.22M | $ 148.51M |
| Total Debt | $ 22.26M | $ 37.18M | $ 70.08M | $ 54.86M | $ 44.87M |
| Net Debt | $ 15.74M | $ 13.21M | $ 77.06M | $ 44.84M | $ 26.17M |
| Total Liabilities | $ 98.29M | $ 119.69M | $ 138.88M | $ 121.43M | $ 130.50M |
| Stockholders' Equity | $ 48.99M | $ 52.14M | $ 22.45M | $ 17.79M | $ 18.02M |
| Cash Flow | |||||
| Free Cash Flow | $ 3.72M | $ 21.31M | $ -1.81M | $ -8.89M | $ -5.72M |
| Operating Cash Flow | $ 18.87M | $ 24.03M | $ -1.44M | $ -1.18M | $ 5.04M |
| Investing Cash Flow | $ -17.40M | $ -6.00M | $ -1.72M | $ -8.20M | $ -11.70M |
| Financing Cash Flow | $ -18.92M | $ 796.00K | $ 6.41M | $ 663.00K | $ 18.68M |
Medexus Pharmaceuticals Inc (DE:P731)
FRANKFURT:P731
